Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
329.20
-3.20 (-0.96%)
Nov 5, 2025, 11:59 AM CET
STO:SOBI Revenue
Swedish Orphan Biovitrum AB had revenue of 7.78B SEK in the quarter ending September 30, 2025, with 12.79% growth. This brings the company's revenue in the last twelve months to 27.85B, up 9.50% year-over-year. In the year 2024, Swedish Orphan Biovitrum AB had annual revenue of 26.03B with 17.65% growth.
Revenue (ttm)
27.85B
Revenue Growth
+9.50%
P/S Ratio
4.11
Revenue / Employee
14.74M
Employees
1,806
Market Cap
114.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.03B | 3.90B | 17.65% |
| Dec 31, 2023 | 22.12B | 3.33B | 17.74% |
| Dec 31, 2022 | 18.79B | 3.26B | 21.00% |
| Dec 31, 2021 | 15.53B | 268.00M | 1.76% |
| Dec 31, 2020 | 15.26B | 1.01B | 7.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Medicover AB | 25.22B |
| Elekta AB | 17.84B |
| Asker Healthcare Group AB | 15.88B |
| AddLife AB | 10.53B |
| Nolato AB | 9.57B |
| Vimian Group AB | 4.65B |
| Vitrolife AB | 3.51B |
Swedish Orphan Biovitrum AB News
- 10 days ago - Data presented at ACR Convergence 2025 highlight Sobi's commitment to advancing care across rare and underserved inflammatory conditions - Benzinga
- 12 days ago - Swedish Orphan Biovitrum AB (BIOVF) Q3 2025 Earnings Call Highlights: Strong Growth and ... - GuruFocus
- 12 days ago - Q3 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript - GuruFocus
- 15 days ago - Swedish Orphan Biovitrum AB (publ) (SWOBY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Swedish Orphan Biovitrum AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 16 days ago - Sobi Q3 Adj. EBITA Rises - Nasdaq
- 16 days ago - Sobi raises 2025 financial forecast after Q3 revenue jumps 21% - Seeking Alpha
- 6 weeks ago - KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - Seeking Alpha